(E)-1-((4-bromobenzylidene)amino)-4-phenyl-1H-imidazol-2-amine | 1215677-84-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (E)-1-((4-bromobenzylidene)amino)-4-phenyl-1H-imidazol-2-amine
• 英文别名: 1-(4-bromobenzylideneamino)-4-phenyl-1H-imidazol-2-amine；1-[(E)-(4-bromophenyl)methylideneamino]-4-phenylimidazol-2-amine
• CAS: 1215677-84-1
• 化学式: C₁₆H₁₃BrN₄
• 分子量: 341.21
• InChiKey: XUSVLPMVGCDCMG-VXLYETTFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  对溴苯甲醛 在 盐酸 、 sodium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 反应 24.0h， 生成 (E)-1-((4-bromobenzylidene)amino)-4-phenyl-1H-imidazol-2-amine
  参考文献：
  名称：

  作为抗血小板药的1-（亚芳基氨基）-4-芳基-1H-咪唑-2-胺衍生物的合理设计和合成。

  摘要：

  根据先前的研究表明indicating基团和唑环对血小板的抗凝活性具有药理作用，合成了一系列结构中同时具有hydr和唑（咪唑）环的化合物，并评估了它们对血小板凝集的抑制作用。这些1-（亚芳基氨基）-4-芳基-1H-咪唑-2-胺衍生物中的两种，化合物4a [（（E）-1-（苄叉基氨基）-4-苯基-1H-咪唑-2-胺]和4 p [（E）-4-苯基-1-（（噻吩-2-基亚甲基）氨基）-1H-咪唑-2-胺]的IC50值类似于乙酰水杨酸作为胶原蛋白的血小板聚集诱导剂。

  DOI：

  10.1002/cmdc.201700123

文献信息

• Synthesis and Biological Activities of 2-Amino-1-arylidenamino Imidazoles as Orally Active Anticancer Agents
  作者：Wen-Tai Li、Der-Ren Hwang、Jen-Shin Song、Ching-Ping Chen、Jiunn-Jye Chuu、Chih-Bo Hu、Heng-Liang Lin、Chen-Lung Huang、Chiung-Yi Huang、Huan-Yi Tseng、Chu-Chung Lin、Tung-Wei Chen、Chi-Hung Lin、Hsin-Sheng Wang、Chien-Chang Shen、Chung-Ming Chang、Yu-Sheng Chao、Chiung-Tong Chen

  DOI：10.1021/jm901501s

  日期：2010.3.25

  2-Amino-1-arylidenaminoimidazoles, a novel class of orally (po) active microtubule-destabilizing anticancer agents, were synthesized. The compounds were designed from a hit compound identified in a drug discovery platform by using cancer cell-based high throughput screening, assay. Selective synthesized compounds exerted cell cytotoxicity against human cancer cells. The underlying mechanisms for the anticancer activity were demonstrated as interacting with the tubulins and inhibiting, microtubule assembly, leading to proliferation inhibition and apoptosis induction in the human tumor cells. Furthermore, two compounds showed in vivo anticancer activities in both po and intravenously (iv) administered routes and prolonged the life spans of murine leukemic P388 cells-inoculated mice. These new po active anti mitotic anticancer agents are to be further examined in preclinical studies and developed for clinical uses.
• Rational Design and Synthesis of 1-(Arylideneamino)-4-aryl-1<i>H</i> -imidazole-2-amine Derivatives as Antiplatelet Agents
  作者：Salimeh Amidi、Marjan Esfahanizadeh、Kimia Tabib、Zohreh Soleimani、Farzad Kobarfard

  DOI：10.1002/cmdc.201700123

  日期：2017.6.21

  Based on previous studies indicating the pharmacophoric role of a hydrazone group and azole rings for antiplatelet aggregation activity, a few series of compounds with both hydrazone and an azole (imidazole) ring in their structures were synthesized, and their platelet aggregation inhibitory effects were evaluated. Two of these 1-(arylideneamino)-4-aryl-1H-imidazole-2-amine derivatives, compounds 4 a

  根据先前的研究表明indicating基团和唑环对血小板的抗凝活性具有药理作用，合成了一系列结构中同时具有hydr和唑（咪唑）环的化合物，并评估了它们对血小板凝集的抑制作用。这些1-（亚芳基氨基）-4-芳基-1H-咪唑-2-胺衍生物中的两种，化合物4a [（（E）-1-（苄叉基氨基）-4-苯基-1H-咪唑-2-胺]和4 p [（E）-4-苯基-1-（（噻吩-2-基亚甲基）氨基）-1H-咪唑-2-胺]的IC50值类似于乙酰水杨酸作为胶原蛋白的血小板聚集诱导剂。